Last updated on March 2019

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis


Brief description of study

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

Clinical Study Identifier: NCT03129100

Contact Investigators or Research Sites near you

Start Over

Marek Krogulec

Lecznica MAK-MED, NZOZ
Nadarzyn, Poland
7.3miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.